Fast Melt Tablets Market Growth To $7.72 Billion By 2030: What’s Driving The Expansion?
Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Fast Melt Tablets Market Value Analysis: What Growth Lies Ahead Over The Forecast Period?
The market for fast melt tablets has demonstrated substantial growth in recent years. This market is projected to expand from $5.33 billion in 2025 to $5.74 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 7.8%. This historical growth is attributable to several factors, including the challenge of swallowing conventional tablets, an increase in pediatric and geriatric populations, the early uptake in allergy and CNS drugs, the rising demand for rapid onset formulations, and the broader availability of OTC fast-dissolving medicines.
The fast melt tablets market size is expected to undergo significant expansion in the coming years. This market is set to reach $7.73 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 7.7%. The anticipated growth within this period stems from an increased focus on patient adherence, a rise in neurological and psychiatric disorders, the demand for convenient drug delivery systems, the expansion of homecare medication usage, and innovations within oral thin-film technologies. Notable trends during the forecast period encompass a growing demand for patient-friendly oral dosage forms, increased application in pediatric and geriatric medications, an expansion of CNS and pain management uses, a rising preference for water-free drug administration, and broader adoption for travel-friendly and emergency situations.
Get A Free Sample Report With In-Depth Market Insights:
Fast Melt Tablets Market Opportunity Drivers: What’s Unlocking New Revenue Potential?
The increasing occurrence of heart attacks is anticipated to drive expansion in the fast melt tablets market moving ahead. A heart attack constitutes a critical medical event where the heart muscle’s blood supply is obstructed, typically by a blood clot or plaque accumulation within the coronary arteries. This surge in heart attack cases is linked to greater intake of processed foods, resulting in elevated cholesterol and increased arterial plaque formation. Fast melt tablets facilitate swift drug absorption, allowing for the rapid administration of vital medications like aspirin or nitroglycerin. This helps avert additional damage during a heart attack, thereby enhancing patient recovery by reinstating blood flow and mitigating the likelihood of serious complications. As an illustration, the British Heart Foundation, a UK-based cardiovascular research charity, reported in September 2025 that an extra one million individuals in the UK might be living with cardiovascular disease by 2030, escalating to two million more than current figures by 2040. This projected increase represents the highest figure ever recorded. Consequently, the escalating frequency of heart attacks is a key factor boosting the expansion of the fast melt tablets market.
Fast Melt Tablets Market Segment Trends And Revenue Contributors
The fast melt tablets market covered in this report is segmented –
1) By Type: Anti Psychotics, Anti Epileptics, Central Nervous System (CNS) Stimulants, Anxiolytics, Anti Parkinsonian Drugs, Anti Hypertensive, Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Anti Allergy Drugs, Proton Pump Inhibitors, Other Types
2) By Indication: Pain Management, Allergy And Respiratory Disorders, Neurological Disorders, Gastrointestinal Disorders, Cardiovascular Disorders, Other Indications
3) By Dosage Form: Oral, Sublingual, Buccal, Chewable
4) By Age Group: Adult, Pediatrics, Geriatrics
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies
Subsegments:
1) By Anti Psychotics: Atypical Antipsychotics, Typical Antipsychotics
2) By Anti Epileptics: Sodium Channel Blockers, Gamma-Aminobutyric Acid (GABA) Analogs
3) By Central Nervous System (CNS) Stimulants: Amphetamines, Methylphenidate, Modafinil
4) By Anxiolytics: Benzodiazepines, Azapirones, Antihistamines
5) By Anti Parkinsonian Drugs: Dopamine Agonists, Monoamine Oxidase-B (MAO-B) Inhibitors, Anticholinergics
6) By Anti Hypertensive: Beta Blockers, Calcium Channel Blockers
7) By Non-Steroidal Anti-Inflammatory Drugs (NSAIDS): Cyclooxygenase-1 (COX-1) Inhibitors
8) By Anti Allergy Drugs: Antihistamines, Leukotriene Receptor Antagonists
9) By Proton Pump Inhibitors: Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole
10) By Other Types: Antiemetics, Antidepressants, Analgesics
Fast Melt Tablets Market Innovation Trends Shaping Future Development
Major companies engaged in the fast melt tablets market are focusing on innovative formulations, such as orally disintegrating tablet (ODT) technologies designed for rapid dissolution without water, to improve medication adherence, convenience, and accessibility for patients with chronic neurological conditions. Orally Disintegrating Tablet (ODT) Technology delivers active ingredients in a fast-melt format that breaks down on the tongue in mere seconds, offering ease of administration for patients experiencing difficulty swallowing traditional tablets or those needing discreet, portable dosing options. For instance, in February2023, Cycle Pharmaceuticals Ltd., a U.K.-based rare disease and specialty pharmaceuticals company, launched TASCENSO ODT (fingolimod), which is the first FDA-approved orally disintegrating tablet for treating relapsing forms of multiple sclerosis (MS) in patients aged 10 years and older. This bioequivalent non-generic ODT, developed using Catalent’s ZYDIS fast-dissolve platform, ensures continuity of care for U.S. patients losing access to Gilenya support services and is supported by Cycle’s dedicated patient platform, Cycle Vita, offering co-pay assistance, bridge programs, and in-home baseline assessments to maintain uninterrupted fingolimod therapy.
Fast Melt Tablets Market Competitive Landscape: Which Companies Lead The Industry?
Major companies operating in the fast melt tablets market are Pfizer Inc., Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Glenmark Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Unichem Laboratories Ltd., Lannett Company Inc., Perrigo Company plc, Catalent Inc., SPI Pharma Inc., Fuji Chemical Industries Co. Ltd., Melt Pharmaceuticals Inc., Akina Inc., Church & Dwight Co. Inc., Windmill Health Products LLC, The Procter & Gamble Company, Hikma Pharmaceuticals plc, Dr. Reddy’s Laboratories Ltd.
View The Full Fast Melt Tablets Market Report:
Fast Melt Tablets Market Geographic Analysis: Where Is Demand Accelerating Fastest?
North America was the largest region in the fast melt tablets market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the fast melt tablets market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
